At BIA’s recent Start-up festival, we caught up with Mark Bartlett, CEO of StoreGene, to learn more about his journey, what drives him, and his advice for founders navigating the world of genomics and startups.
As the BIA Parliament Day marks its 25th year, 50 senior figures from the UK life sciences community are gathering in Westminster to urge bold government action to deliver much-needed growth for the UK economy.
Strategic partnership between Medicines Discovery Catapult and the Crick ensures continued national delivery of KQ Labs, a leading accelerator programme for early-stage innovators.
The Mansion House Accord signed on 13 May and the publication of the Government’s Pensions Investment Review mark the latest developments in the BIA’s campaign to unlock pension funds for life sciences. Here, our Director of Policy and External Affairs, Dr Martin Turner, reflects on how we got to this point and what must happen next.
Brainomix presented a series of new studies at the European Stroke Organisation Conference (ESOC) in Helsinki, solidifying the position of its market-leading Brainomix 360 Stroke as the most clinically validated stroke AI imaging solution.
The proposals outlined in the report are a major step towards realising BIA’s long-held goal of increasing investment from UK pension funds into UK life sciences.
Karen Johal, Senior Director at FTI Consulting LLP, explores how salary sacrifice for pensions offers a smart solution to rising employment costs - helping employers cut costs without cutting staff.
In this blog, Nick Hutchinson, Associate Vice President of Just-Evotec Biologics, provides insight into their new fully continuous end-to-end manufacturing platform while also giving inspiration to young scientists.
Ikarovec has highlighted the therapeutic potential of its approach in geographic atrophy and wet AMD, with presentations at major ophthalmic and gene therapy conferences.
BIA has responded to a HMRC consultation on R&D tax relief advance clearances, supporting government's aim to reduce error and fraud, increasing certainty for R&D tax relief claimants.
We are heading to Boston this June for the BIO International Convention 2025 – one of the world’s largest and most influential gatherings in the life sciences calendar.
Medicines Discovery Catapult's Chemical Protein Stability Assay generates vital data to support drug discovery innovators and will enhance Selvita’s screening platform.
WHO members adopted the pandemic preparedness accord as an international treaty at the World Health Assembly. In this blog, Senior Policy and Public Affairs Manager Linda Bedenik looks at what the agreement means for life sciences.
Poolbeg Pharma announces that the US Food and Drug Administration has granted Orphan Drug Designation to POLB 001 as an oral preventative therapy for T-cell engager bispecific antibody-induced Cytokine Release Syndrome.
The policy landscape for deep biotech has seen remarkable strides over the past year, positioning the UK as a leader in engineering biology innovation.
The UK has a vibrant ecosystem supporting early-stage life science start-ups, with accelerators helping companies raise significantly larger seed rounds and exit more efficiently. Our report highlights a critical gap: there is an urgent need for further support to help companies grow beyond scale, particularly given current headwinds. Addressing this is essential to sustain the UK’s global competitiveness in life sciences.
